Does protracted antiviral therapy impact on HCV-related liver cirrhosis progression?

Figure 1 Behaviour of the applied quantitative liver function test in 35 patients treated with combined antiviral therapy. TOSCA: total overnight salivary caffeine assessment. The knurled line shows which groups are significantly different in the values of TOSCA, in respect to the basal ones; ANCOVA (repeated measure) test, P = 0.0001.

Figure 2 Behaviour of Child-Pugh classification in patients on (n 35) or not on (n 36) combined antiviral therapy. Comparison of the probability curves between treated and non-treated patients was made (Log-rank test). Chi-square test = 8.3, P = 0.004; Hazard ratio = 10.9; 95% CI = 1.75-18.9.